Engineered immune cells take on liver cancer in early trial
NCT ID NCT07039201
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new treatment called CG-102-12C for people with advanced liver cancer that has not responded to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 12 participants to check if the treatment is safe and to see if it can shrink tumors or control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CG-102-12C (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early, small study (only 12 people) focused mainly on safety. The treatment may not shrink tumors, and there are risks of serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital, Medical College of Zhejiang University
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••